Stromal targeted therapies in prostate and renal cancer: New concepts and knowledge

Clinical Genitourinary Cancer

Volumn 9, Issue 1, 2011, Pages 1-2

  Sartor, Oliver ^a   Bruland, Oyvind ^b  

^a TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF OSLO   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; BISPHOSPHONIC ACID DERIVATIVE; CLODRONIC ACID; DENOSUMAB; LEXIDRONAM SAMARIUM SM 153; PAZOPANIB; RADIUM; RADIUM 223; SORAFENIB; STRONTIUM 89; SUNITINIB; UNCLASSIFIED DRUG; ZOLEDRONIC ACID;

BONE METASTASIS; CANCER CELL; CANCER GROWTH; CANCER SURVIVAL; CASTRATION RESISTANT PROSTATE CANCER; CELL PROLIFERATION; CELL THERAPY; EDITORIAL; EXTERNAL BEAM RADIOTHERAPY; EXTRACELLULAR MATRIX; FOLLOW UP; HEMATOPOIETIC CELL; HUMAN; KIDNEY CANCER; MESENCHYME CELL; MICROVASCULAR ENDOTHELIAL CELL; MOLECULARLY TARGETED THERAPY; OSTEOBLAST; OSTEOCLAST; PATHOPHYSIOLOGY; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROSTATE CANCER; RANDOMIZED CONTROLLED TRIAL (TOPIC); STROMA CELL; TUMOR MICROENVIRONMENT;

EXTRACELLULAR MATRIX; FEMALE; HUMANS; KIDNEY NEOPLASMS; MALE; MOLECULAR TARGETED THERAPY; PROSTATIC NEOPLASMS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TUMOR MICROENVIRONMENT;

EID: 80053033767     PISSN: 15587673     EISSN: 19380682     Source Type: Journal    
DOI: 10.1016/j.clgc.2011.08.001     Document Type: Editorial

References (20)

1. D.W. Strand, and S.W. Hayward Modeling stromal-epithelial interactions in disease progress Discov Med 9 2010 504 511
2. K. Pietras, and A. Ostman Hallmarks of cancer: interactions with the tumor stroma Exp Cell Res 316 2010 1324 1331
3. L.K. Chung Prostate carcinoma bone-stroma interaction and its biologic and therapeutic implications Cancer 97 suppl 3 2003 772 778
4. I.D. Kaplan, R. Valdagni, and R.S. Cox Reduction of spinal metastases after preemptive irradiation in prostatic cancer Int J Radiat Oncol Biol Phys 18 1990 1019 1025 (Pubitemid 20182333)
5. A.T. Porter, A.J.B. McEwan, and J.E. Powe Results of a randomized phase III trial to evaluate the efficacy of strontium-89 adjuvant to local field external-beam irradiation in the management of endocrine-resistant metastatic prostate cancer Int J Radiat Oncol Biol Phys 25 1993 805 813 (Pubitemid 23123384)
6. O. Sartor, R.H. Reid, and P.J. Hoskin Samarium-153-EDTMP complex for treatment of painful bone metastases in hormone-refractory prostate cancer Urology 63 2004 940 945 (Pubitemid 38596683)
7. S.K. Imam Advancements in cancer therapy with alpha-emitters: a review Int J Radiat Oncol Biol Phys 51 2001 271 278 (Pubitemid 32758888)
8. S. Nilsson, L. Franzen, and C. Parker Bone-targeted radium-223 in symptomatic, hormone refractory prostate cancer: a randomised, multicenter placebo-controlled phase II study Lancet Oncol 8 2007 587 594 (Pubitemid 46995621)
9. Alpharadin significantly improves overall survival in phase III trial in patients with castration-resistant prostate cancer that has spread to the bone [press release] June 6, 2011 Bayer http://www.press.bayer.com/baynews/baynews. nsf/id/Alpharadin-Significantly-Improves- Overall-Survival-Phase-III-Trial- Patients-Castration-Resistant Accessed: July 15, 2011
10. F. Saad, D.M. Gleason, R. Murray Zoledronic Acid Prostate Cancer Study Group A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma J Natl Cancer Inst 94 2002 1458 1468
11. D.P. Dearnaley, M.D. Mason, and M.K. Parmar Adjuvant therapy with oral sodium clodronate in locally advanced and metastatic prostate cancer: long-term overall survival results from the MRC PR04 and PR05 randomised controlled trials Lancet Oncol 10 2009 872 876
12. M.R. Smith Denosumab to prevent bone metastases DMAB 147 study http://www.aua2011.org/program/plenary.cfm Accessed: July 30, 2011
13. B. Escudier, A. Pluzanska, and P. Koralewski Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial Lancet 370 2011 2103 2111 (Pubitemid 350296300)
14. R.J. Motzer, T.E. Hutson, and P. Tomczak Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma J Clin Oncol 27 2009 3584 3590
15. B. Escudier, T. Eisen, and W.M. Stadler Sorafenib in advanced clear-cell renal-cell carcinoma [published correction appears in N Engl J Med 2007; 357: 203] N Engl J Med 356 2007 125 134 (Pubitemid 46089673)
16. C.N. Sternberg, I.D. Davis, and J. Mardiak Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial J Clin Oncol 28 2010 1061 1068
17. M. Hussain, M.R. Smith, and C. Sweeney Cabozantinib (XL184) in metastatic castration-resistant prostate cancer (mCRPC): results from a phase II randomized discontinuation trial J Clin Oncol 29 suppl 2011 abstr 4516
18. T.K. Choueiri, S.K. Pal, and M.E. Cabanillas Antitumor activity observed in a phase I drugdrug interaction study of cabozantinib (XL184) and rosiglitazone in patients (pts) with renal cell carcinoma (RCC) and differentiated thyroid cancer (DTC) J Clin Oncol 29 suppl 2011 abstr e13042
19. O. Sartor Potential synergistic implications for stromal-targeted radiopharmaceuticals in bone-metastatic prostate cancer Asian J Androl 13 2011 366 368
20. O. Sartor, W. Goeckeler, and O. Bruland Stromal targeted therapy in bone metastatic prostate cancer: promise delivered Asian J Androl 2011 [Epub ahead of print]